In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: The time is now

Circulation

Volumn 103, Issue 23, 2001, Pages 2768-2770

  Fonarow, Gregg C ^a   Ballantyne, Christie M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Coronary disease; Editorials; Hypercholesterolemia; Prevention; Risk factors; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; PRAVASTATIN;

CLINICAL TRIAL; CORONARY ARTERY DISEASE; EDITORIAL; HEART PROTECTION; HOSPITAL CARE; HUMAN; HYPERLIPIDEMIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

EID: 0035849549     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.23.2768     Document Type: Editorial

References (18)

1. From bench to bedside: The future is now
2. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
3. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: Data from the national registry of myocardial infarction 3
4. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: An observational study
5. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease
6. Impact of evidence-based "clinical judgment" on the number of American adults requiring lipidlowering drug therapy based on updated NHANES III data
7. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals
8. The American College of Cardiology Evaluation of Preventative Therapeutics (ACCEPT) study: Attainment of goals for comprehensive risk reduction in patients with coronary disease in the US
9. Myocardial injury: The acute phase response and lipoprotein metabolism
10. Improving quality of care for Medicare patients with acute myocardial infarction: Results from the cooperative cardiovascular project
11. Rationale and design of the cardiac hospitalization atherosclerosis management program at the University of California Los Angeles
12. Strategies for implementing lipid-lowering therapy: Pharmacy-based approach
13. Improved treatment of coronary heart disease by implementation of a cardiac hospitalization atherosclerosis management program: CHAMP
14. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality
15. Early statin treatment following acute myocardial infarction and 1-year survival
16. Beneficial effects of pravastatin (± cholestyramine/niacin) initiated immediately after a coronary event (the randomized lipid-coronary artery disease [L-CAD] study)
17. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial
18. Preventing heart attack and death in patients with coronary disease